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Objectives: Historically, patients with a hematologic malignancy 
have one of the highest mortality rates among cancer patients 
admitted to the ICU. Therefore, physicians are often reluctant to 
admit these patients to the ICU. The aim of our study was to exam-
ine the survival of patients who have a hematologic malignancy 
and multiple organ failure admitted to the ICU.
Design: This retrospective cohort study, part of the HEMA-ICU 
study group, was designed to study the survival of patients with a 
hematologic malignancy and organ failure after admission to the 
ICU. Patients were followed for at least 1 year.
Setting: Five university hospitals in the Netherlands.
Patients: One-thousand ninety-seven patients with a hematologic 
malignancy who were admitted at the ICU.
Interventions: None.
Measurements and Main Results: Primary outcome was 1-year 
survival. Organ failure was categorized as acute kidney injury, 
respiratory failure, hepatic failure, and hemodynamic failure; mul-
tiple organ failure was defined as failure of two or more organs. 
The World Health Organization performance score measured 3 
months after discharge from the ICU was used as a measure of 
functional outcome. The 1-year survival rate among these patients 
was 38%. Multiple organ failure was inversely associated with 
long-term survival, and an absence of respiratory failure was the 
strongest predictor of 1-year survival. The survival rate among 
patients with 2, 3, and 4 failing organs was 27%, 22%, and 8%, 
respectively. Among all surviving patients for which World Health 
Organization scores were available, 39% had a World Health 
Organization performance score of 0–1 3 months after ICU dis-
charge. Functional outcome was not associated with the number 
of failing organs.
Conclusions: Our results suggest that multiple organ failure 
should not be used as a criterion for excluding a patient with a 
hematologic malignancy from admission to the ICU. (Crit Care 
Med 2019; 47:e120–e128)
Key Words: hematologic malignancy; intensive care unit; multiple 
organ failure/mortality; organ failure; prognosis
The mortality rate among patients with various types of malignancies has decreased in recent years, presumably due in part to the development of new targeted treat-
ment options and improved supportive care (1). However, 
aging of our general population has led to an overall increase 
in the number of oncology patients (2, 3), with a resulting 
increase in the number of patients with a hematologic malig-
nancy admitted to the ICU (4, 5). The risk of ICU admission DOI: 10.1097/CCM.0000000000003526
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is particularly high among patients with a hematologic malig-
nancy due to their immunocompromised status, and sepsis 
(including neutropenic sepsis) is the most common reason 
for ICU admission (6). Compared with other cancer patients 
admitted to the ICU, patients with a hematologic malignancy 
are generally more ill, have a higher mortality rate, and have 
a poorer quality of life measured 1 year after discharge from 
the ICU (7–9). Despite their more vulnerable status, physicians 
today are less reluctant to admit hematologic patients to the 
ICU compared with the 1990s (10). Indeed, ICU survival rates 
have improved due in part to improved treatment of hemato-
logic malignancies and improved ICU care (11, 12). However, 
a prospective study of the efficacy of triaging patients with a 
hematologic malignancy for possible ICU admission found 
that 20% of patients who were considered “not sick enough” to 
benefit from ICU support died before hospital discharge (13). 
In the same study, 25% of patients who were considered “too 
sick” to benefit from ICU support survived (13). These statis-
tics indicate that restrictive judgment by clinicians in terms 
of ICU admission can be an alternative explanation for the 
improvement in ICU survival rates.
A reliable prognostic model for patients with a hematologic 
malignancy is still lacking, and recent studies found conflict-
ing results with respect to the value of prognostic factors for 
mortality in critically ill patients with a hematologic malig-
nancy. These factors include neutropenia/leukopenia, the 
Acute Physiology and Chronic Health Evaluation (APACHE) 
II score, and stem cell transplantation status. Consequently, it 
is currently unclear which variables can be used to predict the 
mortality rate of patients with a hematologic malignancy after 
admission to the ICU (14–19).
Organ failure is a well-recognized predictor of ICU-related 
mortality among this patient population (5, 15, 20), and the 
Sequential Organ Failure Assessment (SOFA) score has been 
reported to serve as an independent predictor of mortal-
ity among patients with a hematologic malignancy who are 
admitted to the ICU (14, 21–23). However, the aggregate SOFA 
score lacks information regarding the number of failing organs 
and the specific organ system(s) involved. In addition, most 
published studies that addressed the outcome of patients with 
a hematologic malignancy admitted to the ICU focused pri-
marily on short-term survival (5, 7, 13, 24).
The aim of our study was to examine the 1-year survival 
rate and functional status of patients who have a hematologic 
malignancy and organ failure and were admitted to the ICU. By 
focusing on the contribution of different forms or combina-
tions of nonhematologic organ failure, our results may provide 
a rational and reliable decision model that may help shape the 
policy regarding ICU admission for this patient population.
METHODS
Data Collection
We performed a multicenter retrospective observational study 
for the period from December 2002 to August 2015 using 
prospectively collected data in the Dutch National Intensive 
Care Evaluation (NICE) registry and the Diagnosis Treatment 
Combination Healthcare Cost and Utilization databases at the 
participating medical centers. Where possible, any missing 
information was obtained retrospectively from the patient’s 
electronic medical records. The following five Dutch univer-
sity hospitals participated in this study: the Academic Medi-
cal Center Amsterdam, Erasmus Medical Center (Rotterdam), 
Leiden University Medical Center, Radboud University Medi-
cal Center Nijmegen, and the University Medical Center Gron-
ingen. The participating ICUs were closed-format ICUs and 
held daily multidisciplinary meetings with the hematologist 
and intensivists. Ethics approval was obtained on August 23, 
2016 from the Medical Ethics Committee of the University 
Medical Center Groningen (number METc 2016.396).
We included only patients with a clinically confirmed 
hematologic malignancy who were admitted to the ICU with 
an acute medical or surgical indication. Patients who were 
admitted after elective surgery or for a diagnostic procedure 
(e.g., bronchoscopy) were excluded. Only first ICU admissions 
were included in our analysis. To further exclude nonacute rea-
sons for ICU admission, we also excluded all patients who were 
discharged from the ICU within 24 hours of admission.
We collected the following baseline characteristics: age at the 
time of admission to the ICU, gender, malignancy type, disease 
status at the time of admission, whether mechanical ventila-
tion was needed, the use of vasoactive medication, the reason 
for admission to the ICU, previous stem cell transplantation, 
renal replacement therapy, length of stay at the hospital prior 
to ICU admission, and the presence of infection. Laboratory 
values obtained at the time of ICU admission included biliru-
bin level, creatinine level, neutrophil count, and platelet count. 
Severity of illness within the first 24 hours of ICU admission 
was assessed using the APACHE II score (25).
Survival was measured for up to 1 year. World Health 
Organization (WHO) performance scores were collected 3 
months after ICU discharge at two (Academic Medical Center, 
University of Amsterdam and University Medical Center 
Groninge) of the five participating centers and were used to 
analyze performance at 3 months.
Definitions
Hematologic malignancies were categorized as follows: acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia 
(AML), chronic lymphoblastic leukemia, chronic myeloid leu-
kemia, Hodgkin’s lymphoma (HL), non-HL (NHL), and mul-
tiple myeloma (MM). Disease status was defined as either active 
disease or complete remission, with active disease defined as 
either a lack of complete remission or a relapse.
Patients were categorized based on their reason for admission 
to the ICU as follows: disease-related, sepsis, anaphylactic shock, 
intestinal perforation, pulmonary embolus, neurologic indica-
tion, severe hemorrhaging, treatment-related toxicity, or other.
We focused on four types of organ failure based on the NICE 
criteria used to define organ failure (26, 27). Acute kidney 
injury was defined as the need for renal replacement therapy 
or a creatinine level greater than 133 µmol/L in combination 
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with oliguria within 24 hours of admission to the ICU. Hepatic 
failure was defined as a bilirubin level greater than 102 µmol/L 
within 24 hours of admission to the ICU. Respiratory failure 
was defined as the need for mechanical ventilation within 24 
hours after admission to the ICU. Finally, hemodynamic fail-
ure was defined as the need for vasoactive medication within 
24 hours of admission to the ICU.
We categorized patients with one or more failing organs 
into four main groups based on the number of failing organ 
systems (i.e., 1, 2, 3, or 4 failing organ systems). Multiple 
organ failure (MOF) was defined as the occurrence of two or 
more failing organ systems. In addition, we divided the main 
groups into subgroups based on the type(s) of organ failure, 
using a two-step procedure. First, we grouped patients accord-
ing to the number of (nonhematologic) failing organs. We 
subsequently grouped patients according to the specific fail-
ing organ system(s). For example, patients with acute kidney 
injury and respiratory failure but not hemodynamic failure or 
hepatic failure formed one subgroup.
WHO performance score uses a five-point scale ranging from 
0 to 4, with 0 defined as “able to carry out all normal activity with-
out any restriction” and 4 defined as “completely disabled” (28).
Neutropenia was defined as a neutrophil count less than 
0.5 × 109 cells/L. Infection was defined as the presence of a con-
firmed or suspected infection at the time of admission to the 
ICU or within the first 24 hours after admission; this was based 
on the results of a culture test, a positive Gram stain, periop-
erative findings, or the physician’s judgment.
We considered hematologic failure to be present in virtually 
all of our patients and therefore did not enter it as a distin-
guishing characteristic or type of organ failure. Thus, our study 
assessed the association between nonhematologic organ failure 
and outcome in this high-risk patient population.
Statistical Analyses
Normally distributed continuous data are presented as the 
mean ± sd; categorical data are presented as the number of 
patients with the corresponding percentage. We used descrip-
tive statistics for survival rate.
The primary outcome was survival 1 year after ICU admis-
sion. To compare the association between putative predictors 
of survival, we used the chi-square test (for dichotomous vari-
ables), the Mann-Whitney U test (for nominal variables and 
nonnormally distributed continuous variables), or the Student 
t test (for normally distributed continuous data). All tests were 
two-sided, and a p value of less than 0.05 was considered to 
indicate a statistically significant difference. To determine the 
quality of life of the surviving patients, we examined WHO 
scores obtained by two participating centers 3 months after 
discharge from the ICU. To test whether MOF was related to 
the 3-month WHO score, we performed a landmark analysis 
using an one-way analysis of variance. For this analysis, we 
included only the patients who survived the hospital stay; in 
addition, we classified any patients who died within 3 months 
of discharge from the ICU as “completely disabled” (i.e., a 
WHO performance score of 4).
We studied the association between MOF and survival 
using binary logistic regression, yielding a crude odds ratio 
(OR) with corresponding 95% CI. We ran bivariate analyses 
with all possible confounders and each combination of organ 
failure in order to select variables for our multivariate analy-
ses. If the OR of organ failure/MOF in the bivariate analyses 
did not change more than 10% for any of variable used, we 
considered that organ failure/MOF to be an independent pre-
dictor of survival.
To identify which type of organ failure was most strongly 
associated with long-term outcome, we performed a 
Classification and Regression Tree (CRT) analysis in order to 
create a decision tree, providing a model that predicts the value 
of the dependent variable (i.e., long-term outcome) based on 
the values of the independent variables. The nodes of the CRT 
identify which variables are the most useful for predicting sur-
vival or mortality and what the survival rate is in several sce-
narios. To measure the fraction of patients who were still alive 
up to 1 year after ICU admission, and the effect of MOF on 
survival, we generated Kaplan-Meier survival curves and com-
pared these curves using a log-rank test.
Missing values were considered as missing in our analyses.
RESULTS
A total of 1,097 patients were included in our study. The 
mean age was 55 years, and 37% of patients were female 
(Table 1). All patients had a confirmed hematologic malig-
nancy, with AML (35%), NHL (30%), and MM (13%) 
comprising the most prevalent types of malignancy. The 
survival rates of the ALL, HL, and MM patient groups were 
significantly higher than the average survival rate for the 
entire study population, due in part to the relatively low 
survival rate among patients with AML. A total of 693 
patients (63%) had active disease, which was associated 
with decreased survival. Respiratory failure was the most 
prevalent form of organ failure, occurring in 700 patients 
(64%); hemodynamic failure occurred in 552 of patients 
(50%), acute kidney injury occurred in 167 patients (15%), 
and hepatic failure occurred in 114 patients (10%). Only 12 
of the 1,097 patients (1.1%) had organ failure involving all 
four nonhematologic organ systems.
Outcome
The survival rate 28 days, 3 months, and 1 year after ICU admis-
sion was 56% (618 patients), 48% (524 patients), and 38% 
(413 patients), respectively. We found no significant difference 
between the five participating centers with respect to survival. 
Although the average age of the survivors was slightly lower 
than the nonsurvivors, neither age nor gender was associated 
with survival. Sepsis was the most common reason for admis-
sion to the ICU but was not associated with survival. Approxi-
mately one fifth of the patients (21%) received an allogeneic 
stem cell transplantation prior to admission to the ICU, and 
this was associated with decreased survival. Compared with 
nonsurvivors, the survivors had a significantly lower APACHE 
II score, with a mean overall score of 26.
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TABLE 1. Baseline Characteristics of All 1,097 Patients at Baseline and the Surviving and 
Nonsurviving Patients at 1 Year
Characteristic
Baseline,  
n = 1,097
Survivors at 1 yr,  
n = 413
Nonsurvivors,  
n = 684 p
Hospital    0.31
Female, n (%) 401 (37) 152 (38) 249 (62) 0.87
Mean age, yr, mean ± sd 55 ± 15 54 ± 15 56 ± 14 0.09
Malignancy, n (%)    < 0.01
  Acute lymphoblastic leukemia 76 (7) 37(49) 39 (51)  
  Acute myeloid leukemia 387 (35) 118 (30) 269 (70)  
  Chronic lymphoblastic leukemia 68 (6) 24 (35) 44 (65)  
  Chronic myeloid leukemia 47 (4) 15 (32) 32 (68)  
  Hodgkin’s lymphoma 44 (4) 24 (55) 20 (45)  
  Non-Hodgkin’s lymphoma 329 (30) 123 (37) 206 (63)  
  Multiple myeloma 146 (13) 74 (49) 72 (51)  
Organ failure, n (%)     
 Hepatic failurea 114 (10) 32 (28) 82 (72) 0.01
 Acute kidney injury 167 (15) 39 (23) 128 (77) < 0.01
 Respiratory failure 700 (64) 201 (29) 499 (71) < 0.01
 Hemodynamic failure 552 (50) 175 (32) 377 (68) < 0.01
Active disease, n (%) 693 (63) 231(33) 462 (67) < 0.01
Platelet count, × 103/μL, mean ± sd 90 ± 121 116 ± 135 75 ± 109 < 0.01
Neutropenia, n (%) 309 (28) 108 (35) 201 (65) 0.17
APACHE II score, mean ± sd 26 ± 18 23 ± 15 27 ± 19 < 0.01
High APACHE II score (> 22) , n (%) 520 (47) 163 (31) 357 (69) < 0.01
Reason for admission to the ICU, n (%)  
 Disease related 199 (18) 67 (34) 132 (66) 0.15
 Sepsis 543 (50) 206 (38) 337 (62) 0.82
 Anaphylactic shock 12 (1) 9 (75) 3 (25) 0.01
 Intestinal perforation 34 (3) 13 (38) 21 (62) 0.94
 Pulmonary embolus 15 (1) 8 (53) 7 (47) 0.21
 Neurologic indication 75 (7) 30 (40) 45 (60) 0.66
 Hemorrhage 71 (7) 16 (23) 55 (77) 0.01
 Treatment-related toxicity 32 (3) 11(34) 21 (66) 0.70
 Other 115 (11) 53 (46) 62 (54) 0.05
Stem cell transplantation, n (%) 307 (28) 108 (35) 199 (65) 0.02
 Allogeneic 226 (21) 70 (31) 156 (69) 0.02
 Autologous 81 (7) 38 (47) 43 (53) 0.07
Infection, n (%) 499 (46) 163 (33) 336 (67) < 0.01
Length of hospital stay prior to ICU 
admission, db, mean ± sd
11 ± 14 9 ± 12 12 ± 14 < 0.01
APACHE = acute physiology and chronic health evaluation. 
a Hepatic failure values were missing for 91 patients.
b Values were missing for 280 patients; therefore, these data are shown for illustration purposes only and were not used for further analyses.
Boldface values indicate p < 0.05 (statistically significant difference).
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WHO performance score 
was available for 493 patients. 
Among the patients who sur-
vived their hospital stay, 39% 
had a WHO performance 
score of 0 or 1 3 months after 
discharge from the ICU, with a 
mean score of 1.83. Although 
the number of failing organ 
systems was inversely associ-
ated with survival (Fig. 1), it 
was not associated with the 
WHO performance score mea-
sured 3 months after ICU dis-
charge (p = 0.42).
Among the patients with 
“only” one failing organ, 
the 1-year survival rate was 
similar to the overall 1-year 
survival rate (i.e., 38%). 
However, having “at least” 
one or more failing organs 
was strongly inversely asso-
ciated with survival, and the 
survival rate in these patients 
depended largely on the spe-
cific combination of failing 
organs (Fig. 2 and Table 2). 
(Table 3)Figure 1. Kaplan-Meier survival curve for patients with 0, 1, 2, 3, or 4 failing organ systems.
Figure 2. Forest plot showing the odds ratio (OR) and corresponding 95% CI for 1-yr survival in patients with either single organ failure (OF) or multiple 
OF (MOF). A, OR for patients with at least the indicated type of single OF or MOF; for example, a patient with acute kidney injury (AKI) also includes 
patients with AKI and hepatic failure (HF). B. OR for patients with exactly the indicated type of OF. Note that one patient with exactly AKI + HF and the 
three patients with exactly AKI + HF + respiratory failure (RF) had a 0% survival rate; thus, an OR could not be calculated for these two type of MOF. 
See also Table 2. HDF = hemodynamic failure.
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Among the patients with two failing organs, the 1-year sur-
vival rate was 27%. The survival rate was similar for all patients 
with two or more failing organs (26%), and this decreased only 
slightly (to 22%) for patients with three failing organs. As men-
tioned above, only 12 patients had four failing organ systems, 
and the 1-year survival rate was 8%; however, it should be 
noted that only one of the 12 patients with four failing organ 
systems survived the ICU and was discharged. This patient had 
a 3-month WHO performance score of 2, indicating that he/
she was ambulatory, able to care for himself/herself, and up 
and about more than 50% of the waking hours but was unable 
to hold employment.
Our analysis revealed that MOF is an independent pre-
dictor of survival. Platelet count was the only factor that 
affected survival among patients with three failing organs; 
specifically, survival decreased from 22% to 14% when these 
patients had a concomitant platelet count below the median 
value of 44 × 103/μL. The nodes in the CRT analysis were split 
based only on significant predictors, starting with the most 
important predictor as the parent node (Fig. 3). The need for 
mechanical ventilation was the strongest predictor of survival. 
The lowest survival rate was seen in node 6, with only 19% of 
patients in this node (i.e., both respiratory failure and acute 
kidney injury) surviving. In contrast, the lowest mortality rate 
was seen in node 7 (i.e., patients who did not have respiratory 
failure, kidney failure, or hemodynamic failure), with a 1-year 
survival rate of 65%.
DISCUSSION
In our cohort of more than 1,000 patients with a hematologic 
malignancy admitted to the ICU, we found that MOF was 
inversely associated with survival, although the survival rate 
was relatively high and nearly half of the survivors had a good 
WHO performance score. The specific combination of organ 
systems that fail can help the clinician identify the patient 
groups with the highest and lowest survival rates. Respiratory 
failure appeared to be the most important determinant of sur-
vival. For example, patients with both respiratory failure and 
TABLE 2. Survival Rate and Odds Ratio 1 Year After ICU Admission for All Possible 
Combinations of Organ Failure Compared With the Entire Study Population
Failing Organ(s)
With at Least This Type of  
Organ Failure or MOF Combination
With Exactly This Type of  
Organ Failure or MOF Combination
n
Survival 
Rate, % OR (95% CI) n
Survival 
Rate OR (95% CI)
One failing organ 916 32 0.24 (0.17–0.34) 438 38 1.11 (0.87–1.43)
 AKI 167 23 0.44 (0.30–0.64) 19 47 1.50 (0.60–3.72)
 RF 700 29 0.35 (0.27–0.45) 279 33 0.75 (0.56–0.99)
 HDF 552 32 0.59 (0.46–0.75) 124 50 1.77 (1.22–2.58)
 HF 114 27 0.58 (0.38–0.89) 16 38 0.98 (0.36–2.73)
Two failing organs 478 26 0.39 (0.30–0.51) 351 27 0.50 (0.38–0.67)
 AKI+ HF 24 21 0.42 (0.16–1.14) 1 0 NA
 AKI + RF 101 19 0.35 (0.21–0.59) 17 29 0.69 (0.24–1.96)
 AKI + HDF 127 19 0.35 (0.22–0.55) 38 16 0.30 (0.12–0.72)
 HF + RF 79 22 0.42 (0.24–0.74) 29 21 0.42 (0.17–1.04)
 HF + HDF 65 29 0.66 (0.38–1.14) 10 40 1.09 (0.31–3.90)
 HDF + RF 372 26 0.46 (0.35–0.61) 256 29 0.60 (0.44–0.81)
Three failing organs 127 22 0.42 (0.27–0.66) 115 22 0.47 (0.30–0.74)a
 AKI + HF + RF 15 7 0.12 (0.02–0.88) 3 0 NA
 AKI + HF + HDF 20 25 0.54 (0.20–1.50) 8 50 1.65 (0.41–6.62)
 AKI + RF + HDF 81 17 0.32 (0.18–0.58) 69 19 0.36 (0.20–0.67)
 RF + HDF + HF 47 23 0.49 (0.24–0.97) 35 29 0.64 (0.31–1.36)
Four failing organs       
 AKI + HF + RF + HDF 12 8 0.15 (0.02–1.14) 12 8 0.15 (0.02–1.14)
AKI = acute kidney injury, HDF = hemodynamic failure, HF = hepatic failure, MOF = multiple organ failure, NA = not applicable, OR = odds ratio,  
RF = respiratory failure.
a OR (95% CI) changed to 0.53 (0.33–0.86) when platelet count was included in the analysis. Thus, the survival rate with exactly 3 failing organs is only 14% 
when combined with a platelet count of < 44 × 103/μL.
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acute kidney injury had only a 
19% survival rate, compared 
with 54% of patients without 
respiratory failure. Importantly, 
the overall 38% 1-year survival 
rate is encouraging, particularly 
given that up to 84% of these 
survivors had at least one fail-
ing organ system. The average 
survival rate, APACHE II score, 
age, and baseline characteristics 
of our patient cohort were con-
sistent with previous European 
studies (5, 9, 12, 16, 20, 21, 24, 29); 
thus, we conclude that the large, 
heterogeneous population in 
this multicenter study likely 
reflects the general population, 
indicating that our results pro-
vide added value with respect to 
clinical decision-making.
The survival rates associ-
ated with MOF in our patient 
cohort were higher than previ-
ous reports (7, 20, 24, 30), and 
our results obtained for patients 
with hemodynamic failure 
clearly support this higher rate; 
even though hemodynamic fail-
ure was a predictor of decreased 
survival, nearly one in three 
patients survived, even when 
combined with another type of 
organ failure. This finding is in 
contrast with previous studies in 
which none of the patients who 
were taking vasoactive medica-
tion and had both organ failure 
and leukopenia survived (16, 
31). These data suggest that the 
occurrence of MOF should not 
necessarily be an exclusion cri-
terion for admission to the ICU. 
Given that previous studies used 
the SOFA score to define organ 
failure, it is unclear which fac-
tor used to calculate the SOFA 
score was responsible for the 
association between SOFA 
score and mortality (14, 21–23). 
Furthermore, the value of using 
the SOFA score to predict sur-
vival can vary, as some studies 
found that the SOFA score was 
an independent predictor of ICU 
mortality, whereas other studies 
Figure 3. Classification 
and Regression Tree 
analysis and resulting 
decision tree for patients 
who were alive or not 
1 yr after admission to 
the ICU. Note that the 
197 patients in node 7 
includes 16 patients who 
had hepatic failure but 
no other failing organ. 
The nodes ranked from 
the lowest survival rate to 
the highest survival rate. 
AKI = acute kidney injury, 
CVVH = continuous veno-
venous hemofiltration,  
HDF = hemodynamic 
failure, HF = hepatic failure, 
RF = respiratory failure.
Nodes Organ Failure Combination 1-yr Survival Rate, %
6 RF + AKI 19
10 RF + no AKI + HF 25
2 RF 29
4 No RF + AKI 29
12 RF + no AKI + no HF + HDF 29
5 RF + no AKI 30
9 RF +no AKI + no HF 31
11 RF + no AKI + no HF + no HDF 33
8 No RF + no AKI + HDF 49
1 No RF 54
3 No RF + no AKI 59
7 No RF + no AKI + no HDF 65
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found no such association (19, 24, 29). By defining organ fail-
ure using our specific criteria, we were able to examine the 
association between survival and specific forms and combina-
tions of organ failure, providing added value compared with 
the prediction models used in other studies. Furthermore, our 
relatively large dataset enabled us to perform a CRT analysis, 
which can be helpful in clinical decision-making, as the effect 
of each variable can be measured and displayed clearly.
Another strength of our study is our concrete primary end-
point (1-yr survival), which was possible due to the relatively 
long-term follow-up period. Finally, the NICE registry is con-
sidered to be a reliable source of high-quality data (32).
Despite its strengths, our study had several limitations 
that warrant discussion. First, our retrospective evaluation of 
prospectively collected data could have led to selection bias. 
Although the mean APACHE score in our patient population 
was similar to other studies, we cannot rule out the possibil-
ity that some patients who were considered too sick were not 
admitted to the ICU. However, we do not believe this was likely 
a major issue in our analysis given the high average APACHE 
II scores in our patient population. Second, the relatively 
large time window (spanning approximately 13 yr) for the 
data included in our study may have influenced the results. 
However, the survival rates among our patients were similar—
or higher—than previous studies. Third, complete functional 
outcome scores were not available for all patients. Finally, the 
definitions that we used for organ failure were based on the 
NICE criteria and therefore could have differed slightly from 
international definitions of organ failure such as the SOFA 
score (26, 27). Furthermore, the Glasgow Coma Score was not 
taken into account as a measure of a separate type of organ fail-
ure. However, we previously examined the association between 
CNS function and survival and found that patients with a his-
tory of hematologic malignancy who present with a critical 
neurologic event have a survival rate similar to other patients 
with a hematologic malignancy admitted to the ICU (33).
It would be interesting to expand the decision tree by adding 
additional relevant parameters such as duration of the hospi-
tal stay prior to admission to the ICU. The association between 
MOF and decreased survival indicates that the risk of develop-
ing MOF could serve as an indication to admit these patients 
to the ICU as early as possible; furthermore, previous studies 
found that a longer hospital stay prior to ICU admission is pre-
dictive of mortality (5, 24). We also found that the duration of 
time in the hospital prior to admission to the ICU was associ-
ated with survival (data not shown); however, due to missing 
values, we were unable to add this variable to the decision tree. 
In addition, the length of the stay in the ICU and the duration 
of life-supporting interventions could be relevant factors in 
determining and predicting survival. For example, the sooner 
the patient can be stabilized, the sooner the treatment for the 
underlying hematologic malignancy can resume; this will likely 
improve long-term survival, as recent studies showed that long-
term survival among patients with a hematologic malignancy 
depends strongly on the ability of the patient to resume treat-
ment for the underlying malignancy (34, 35).
Our study yielded additional findings that may be clinically 
relevant, including the presence of active disease, low plate-
let count (thrombocytopenia), and the type of hematologic 
malignancy. Our finding that active disease—an indicator of 
disease status—is correlated with a decreased 1-year survival 
rate is in contrast to other studies (36). Furthermore, throm-
bocytopenia—a common complication among patients with a 
hematologic malignancy due to chemotherapy, disseminated 
intravascular coagulation, or bone marrow failure—has been 
related to MOF (37).
CONCLUSIONS
Here, we provide clear evidence that that organ failure is a 
predictor of decreased 1-year survival among patients with 
a hematologic malignancy in the ICU. In particular, the need 
for mechanical ventilation (i.e., respiratory failure) had the 
strongest inverse association with long-term outcome. Nev-
ertheless, we believe that MOF should not be used as an 
exclusion criterion for admission to the ICU, as survival 
rate was still relatively high even among patients with two 
or more failing organ systems. Furthermore, with respect 
to long-term function, we found no difference in 3-month 
WHO performance scores between survivors with no organ 
failure and survivors who had multiple failing organ systems 
while in the ICU.
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